Endobronchial Valve Therapy as a
Standard of Care Treatment
Chronic Obstructive Pulmonary Disease or COPD is a prevalent chronic condition worldwide, ranking as the third leading cause of death across Western countries.
The way that COPD, including severe emphysema, is treated is changing. Treatment with Bronchoscopic Lung Volume Reduction, such as the Zephyr® Endobronchial Valve, is now a standard of care option.
Expert Insights
To get a greater understanding of this potentially life-changing procedure, hear from some experts in the field of respiratory medicine.
Watch the Interview
“What we’ve seen with endobronchial valves is what I would describe as life-changing improvements. When some of these patients improve, they get massive improvements. Their lung function improves by about 30%. They’re able to walk again. They’re able to comfortably go outside. So, not only are we giving them improvements in their lung capacity, what we’re really giving them is their dignity and their function back,” says Prof. Shah.
Clinical Evidence
There is substantial clinical evidence stemming from a number of randomised controlled clinical trials that have contributed to the development of endobronchial valve treatment, and it is, therefore, now considered an important part of the overall management in patients with COPD.
Explore the wealth of clinical evidence supporting the efficacy of Zephyr Valves in severe COPD/emphysema management.
Prof. Shah is an actual Zephyr Valve Treating doctor who was compensated to participate in this video.
EUR-EN-2247-v1
